NEW YORK, June 11, 2026 (GLOBE NEWSWIRE) -- Neion Bio, a biotechnology company revolutionizing the production of biologic medicines, today announced the close of an oversubscribed $23 million Series A financing to further advance its novel manufacturing platform and expand its growing pipeline of products. The financing was led by Caffeinated Capital, an early investor in Neion, with participation from new investors, Digitalis Ventures, Ensemble VC, and Trust Ventures alongside significant follow-on investment from existing investors Haystack and Basis Set Ventures, among others. Neion Bio utilizes frontier genetic engineering to turn chicken eggs into medicine factories for the production of complex, glycosylated proteins.

"Significant advances in foundational engineering tools in biology are enabling Neion Bio to unlock the next bioindustrial revolution," said Dimi Kellari, co-founder and CEO of Neion Bio. "We are grateful to partner with forward-thinking deep technology investors who share our conviction in both the challenges facing biologics manufacturing today and the opportunity to fundamentally reshape it."

"Neion Bio is redefining biologics manufacturing at a time when securing domestic supply chains and access to critical medicines has become a top national priority," said Varun Gupta, Partner at Caffeinated ...